Rinvoq ER 45 MG tablet UU 28S
Ended Awarded
- Contract number
- SPE2DB25FAVXA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $46,057
Award facts
- Contract value 100% obligated
- $46,057.47 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $46,057.47 to DMS Pharmaceutical Group Inc. for RINVOQ ER 45 mg tablets (28-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order with a place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 4, 2025. This award carries no set-aside designation, allowing the vendor to compete on an unrestricted basis within the federal marketplace.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency, valued at $499.9 million and valid through November 2026. The IDC, established under the SPE2DB program, enables DLA to issue firm fixed-price delivery orders for pharmaceutical products supporting military health facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently delivering a diverse portfolio of branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. RINVOQ ER (upadacitinib extended-release) is a Janus kinase inhibitor used in treating rheumatoid arthritis and other inflammatory conditions, demonstrating the vendor's role in supplying specialty pharmaceutical products to military medical systems.
Quick answers
Who was awarded contract SPE2DB25FAVXA?
SPE2DB25FAVXA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 1, 2025.
How much is contract SPE2DB25FAVXA worth?
The government has obligated $46,057 on SPE2DB25FAVXA.
Is contract SPE2DB25FAVXA an order under another contract?
Yes. SPE2DB25FAVXA is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB25FAVXA competed?
The extent of competition for SPE2DB25FAVXA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award